[Research progress of CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma]

Authors :: J J, Yang
W, Sang
K L, Xu
Source :: Zhonghua nei ke za zhi. 58(11)
Publication Year :: 2019
Abstract: 弥漫大B细胞淋巴瘤是一类具有明显异质性的恶性肿瘤，部分为复发或难治患者，预后很差。嵌合抗原受体（CAR）-T细胞是一种新的治疗恶性肿瘤策略，多项临床试验已证实其有效性，但预处理方案、免疫抑制微环境等会影响其疗效。另外，CAR-T细胞疗法也存在脱靶效应、细胞因子释放综合征、神经毒性等问题。.

Subjects :: Receptors, Chimeric Antigen
T-Lymphocytes
Cell- and Tissue-Based Therapy
Humans
Lymphoma, Large B-Cell, Diffuse
Neoplasm Recurrence, Local
Immunotherapy, Adoptive

Tools